Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Clinical Trials
31
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults
- Conditions
- ShinglesVaccine-Preventable DiseasesHerpes Zoster
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 440
- Registration Number
- NCT06569823
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- PlagueVaccine-Preventable DiseasesPlague, Pneumonic
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05506969
- Locations
- 🇺🇸
Optimal Research Alabama, Huntsville, Alabama, United States
🇺🇸Optimal Research California, San Diego, California, United States
🇺🇸Optimal Research Florida, Melbourne, Florida, United States
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
- Conditions
- ShinglesVaccine-Preventable DiseasesHerpes Zoster
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT05245838
- Locations
- 🇦🇺
Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
- Conditions
- End Stage Renal Disease on Hemodialysis (Diagnosis)
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 119
- Registration Number
- NCT03934736
- Locations
- 🇺🇸
DaVita Clinical Research or Affiliate, Milwaukee, Wisconsin, United States
DV2-HBV-27: Observational Pregnancy Registry
- Conditions
- Pregnant
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT03664648
- Locations
- 🇺🇸
PPD Registry Office, Recruiting Nationwide, Wilmington, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Sonoma Biotherapeutics Strengthens Leadership Team with Appointment of Rajesh Krishnan as Chief Technical Officer
• Sonoma Biotherapeutics has appointed Rajesh Krishnan, Ph.D., as Chief Technical Officer to advance their engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. • Dr. Krishnan brings over 25 years of industry experience in process development and manufacturing, most recently serving as CTO and CSO at Oncternal Therapeutics with previous leadership roles at Dynavax, Gilead, Merck, Amgen, and Pfizer. • The strategic appointment comes at a crucial time for the clinical-stage biotech company as they continue developing novel treatments aimed at restoring immune system balance through proprietary Treg cell therapy platforms.
Dynavax Reports Strong Growth with HEPLISAV-B Revenue Up 26% in 2024, Advances Pipeline Programs
HEPLISAV-B achieved record net product revenue of $268.4 million in 2024, representing a 26% year-over-year growth, with market share reaching 44% in the U.S. hepatitis B vaccine market.
Goldman Sachs Downgrades Dynavax on Competitive Pressures in Shingles and Hepatitis B Markets
Goldman Sachs has downgraded Dynavax Technologies to Sell from Neutral, reducing price target to $12 amid growing competition in the shingles vaccine market and uncertainties around Z-1018 program.
HepB-CpG Vaccine Shows Superior Response in HIV Patients Non-Responsive to Traditional Hepatitis B Vaccine
A phase 3 trial showed HepB-CpG vaccine achieved superior seroprotection in HIV patients who did not respond to prior HepB-alum vaccination.